Af­ter a “com­pre­hen­sive eval­u­a­tion,” Bris­tol My­ers Squibb has pulled out of its part­ner­ship with Cel­lares and the cell ther­a­py man­u­fac­tur­er will re­struc­ture as a re­sult...

Cell ther­a­py man­u­fac­tur­ing start­up Cel­lares is de­fend­ing it­self against Bris­tol My­ers Squibb af­ter the drug­mak­er pulled out of a con­tract claim­ing Cel­lares’ com­mer­cial man­u­fac­tur­ing tech­nol­o­gy...

Rayze­Bio plots new build: Bris­tol My­ers Squib­b's sub­sidiary plans to in­vest more than $173 mil­lionto con­struct a new 450,000-square-foot ra­dio­phar­ma fac­to­ry in Whitestown, IN...

The FDA gave the green light to a high­ly an­tic­i­pat­ed pan­cre­at­ic can­cer treat­ment that has al­tered the prospects for pa­tients fac­ing the dead­ly dis­ease.

The...

Jazz Phar­ma­ceu­ti­cals’ bis­pe­cif­ic an­ti­body Zi­ihera won a la­bel ex­pan­sion to treat cer­tain pa­tients with gas­tric can­cer.

It’s the first time Zi­ihera will be mar­ket­ed to...

HHS Sec­re­tary Robert F. Kennedy Jr. wants the gov­ern­ment to con­sid­er soft­en­ing its rec­om­men­da­tions for cer­tain vac­cines.

The re­quest for in­for­ma­tion is­sued Fri­day, which Kennedy...